Axonics (AXNX) Revenue & Revenue Breakdown
Axonics Revenue Highlights
Latest Revenue (Y)
$366.38M
Latest Revenue (Q)
$114.56M
Main Segment (Y)
Sacral Neuromodulation
Main Geography (Y)
UNITED STATES
Axonics Revenue by Period
Axonics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $366.38M | 33.86% |
| 2022-12-31 | $273.70M | 51.81% |
| 2021-12-31 | $180.29M | 61.64% |
| 2020-12-31 | $111.53M | 707.05% |
| 2019-12-31 | $13.82M | 1854.74% |
| 2018-12-31 | $707.00K | 451.84% |
| 2017-12-31 | $128.12K | 100.00% |
| 2016-12-31 | - | - |
Axonics generated $366.38M in revenue during NA 2023, up 33.86% compared to the previous quarter, and up 51821.64% compared to the same period a year ago.
Axonics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $114.56M | 25.33% |
| 2024-03-31 | $91.41M | -16.70% |
| 2023-12-31 | $109.73M | 17.87% |
| 2023-09-30 | $93.10M | 310.06% |
| 2023-06-30 | $22.70M | -67.86% |
| 2023-03-31 | $70.65M | -17.77% |
| 2022-12-31 | $85.92M | 22.07% |
| 2022-09-30 | $70.38M | 2.04% |
| 2022-06-30 | $68.98M | 42.46% |
| 2022-03-31 | $48.42M | -8.87% |
| 2021-12-31 | $53.13M | 13.26% |
| 2021-09-30 | $46.91M | 2.28% |
| 2021-06-30 | $45.87M | 33.44% |
| 2021-03-31 | $34.37M | -1.18% |
| 2020-12-31 | $34.78M | -1.31% |
| 2020-09-30 | $35.24M | 131.66% |
| 2020-06-30 | $15.21M | -42.15% |
| 2020-03-31 | $26.30M | 164.39% |
| 2019-12-31 | $9.95M | 659.82% |
| 2019-09-30 | $1.31M | -12.03% |
| 2019-06-30 | $1.49M | 38.16% |
| 2019-03-31 | $1.08M | 118.02% |
| 2018-12-31 | $494.00K | 145.77% |
| 2018-09-30 | $201.00K | 1575.00% |
| 2018-06-30 | $12.00K | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $118.00 | -99.91% |
| 2017-09-30 | $128.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Axonics generated $114.56M in revenue during Q2 2024, up 25.33% compared to the previous quarter, and up 162.16% compared to the same period a year ago.
Axonics Revenue Breakdown
Axonics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| Bulkamid | $74.57M |
| Sacral Neuromodulation | $291.81M |
Axonics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Sacral Neuromodulation (79.65%), and Bulkamid (20.35%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|
| Sacral Neuromodulation | $91.22M | $71.68M | $217.86M | $73.95M | $40.19M | $32.90M |
| Bulkamid | $23.35M | $19.73M | $55.42M | $19.15M | $5.67M | $1.47M |
Axonics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Sacral Neuromodulation (79.62%), and Bulkamid (20.38%).
Axonics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $15.54M | $5.13M | $3.75M | $3.99M | $5.44M |
| UNITED STATES | $284.85M | $216.86M | $153.84M | $107.54M | $8.38M |
Axonics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (94.83%), and Non-US (5.17%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $5.04M | $4.51M | $8.68M | $3.57M | $1.98M | $1.30M | $1.24M | $1.25M | $1.29M | $1.35M | $722.00K | $922.00K | $4.25M | $2.05M | $1.07M | $1.10M | $565.00K | $1.25M |
| UNITED STATES | $89.08M | $69.84M | $86.58M | $72.21M | $72.20M | $53.85M | $69.07M | $55.61M | $54.47M | $37.72M | $43.70M | $39.15M | $41.61M | $32.32M | $33.71M | $34.14M | $14.65M | $25.05M |
Axonics's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (94.64%), and Non-US (5.36%).
Axonics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MDT | Medtronic | $32.36B | $7.92B |
| BRKR | Bruker | $2.96B | $800.70M |
| ITGR | Integer | $1.60B | $753.01M |
| IART | Integra LifeSciences | $1.54B | $418.18M |
| CNMD | CONMED | $1.24B | $332.10M |
| LIVN | LivaNova | $1.15B | $318.60M |
| IRTC | iRhythm | $492.68M | $148.05M |
| AXNX | Axonics | $366.38M | $114.56M |
| GKOS | Glaukos | $314.71M | $95.69M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $39.97M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| NNOX | Nano-X Imaging | $9.90M | $2.55M |
| MGRM | Monogram Orthopaedics | $365.00K | - |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
AXNX Revenue FAQ
What is Axonics’s yearly revenue?
Axonics's yearly revenue for 2023 was $366.38M, representing an increase of 33.86% compared to 2022. The company's yearly revenue for 2022 was $273.7M, representing an increase of 51.81% compared to 2021. AXNX's yearly revenue for 2021 was $180.29M, representing an increase of 61.64% compared to 2020.
What is Axonics’s quarterly revenue?
Axonics's quarterly revenue for Q2 2024 was $114.56M, a 25.33% increase from the previous quarter (Q1 2024), and a 404.60% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $91.41M, a -16.70% decrease from the previous quarter (Q4 2023), and a 29.38% increase year-over-year (Q1 2023). AXNX's quarterly revenue for Q4 2023 was $109.74M, a 17.87% increase from the previous quarter (Q3 2023), and a 27.72% increase year-over-year (Q4 2022).
What is Axonics’s revenue growth rate?
Axonics's revenue growth rate for the last 3 years (2021-2023) was 103.22%, and for the last 5 years (2019-2023) was 2551.08%.
What are Axonics’s revenue streams?
Axonics's revenue streams in c 23 are Bulkamid, and Sacral Neuromodulation. Bulkamid generated $74.57M in revenue, accounting 20.35% of the company's total revenue Sacral Neuromodulation generated $291.8M in revenue, accounting 79.65% of the company's total revenue
What is Axonics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Axonics was Sacral Neuromodulation. This segment made a revenue of $291.8M, representing 79.65% of the company's total revenue.